Tag: Cancer: Prostate
Dementia With Lewy Bodies Risk Down With α-1 Adrenergic Receptor Antagonists
Risk for developing DLB was lower for men newly started on Tz/Dz/Az compared with those taking tamsulosin or 5ARI
First-Line Biparametric MRI Less Cost-Effective Than PSA for Prostate Cancer Screening
First-line PSA screening remained cost-effective even if bpMRI was free and all men with low-risk prostate cancer underwent surveillance
Active Surveillance Effective Strategy for Favorable-Risk Prostate Cancer
At 10 years after diagnosis, estimated rates of metastasis and prostate cancer-related death were 1.4 and 0.1 percent
Neoadjuvant Chemohormonal Therapy Aids Locally Advanced Prostate Cancer
Significant benefits in terms of three-year biochemical progression-free survival seen for NCHT versus neoadjuvant hormonal therapy
New Prostate Cancer Urine Test Has High Diagnostic Accuracy
Higher AUROC seen for 18-gene MPS2 model compared with current guideline-endorsed biomarkers
HYPORT Noninferior for GU, GI Toxicity in Prostate Cancer
24-month differences in genitourinary and gastrointestinal change scores were noninferior for HYPORT versus COPORT
Single Invitation for PSA Screening Cuts Prostate Cancer Deaths
Small, but significant reduction seen in prostate cancer deaths, but no reduction seen in all-cause mortality
Number of Prostate Cancer Cases Set to Increase to 2.9 Million in 2040
Large increases in prostate cancer expected due to changing age structure and improving life expectancy
MRI + Blood Test Results May Cut Unnecessary Biopsies for Prostate Cancer
Patient-tailored biopsy decisions still maintain high sensitivity
